[
  {
    "ts": null,
    "headline": "Pfizer Stock Surges After Company Makes a Deal With President Trump",
    "summary": "Pfizer shares jumped 6.83% Tuesday after President Trump said the drugmaker would offer some of its drugs on a new direct-to-consumer website and would introduce new drugs to the U.S. market at reduced prices.",
    "url": "https://finnhub.io/api/news?id=7d92d7b7741021982a383fc4de2cc1217781dc0f90208cc0b66ef8179cf823cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759266883,
      "headline": "Pfizer Stock Surges After Company Makes a Deal With President Trump",
      "id": 136943999,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pfizer shares jumped 6.83% Tuesday after President Trump said the drugmaker would offer some of its drugs on a new direct-to-consumer website and would introduce new drugs to the U.S. market at reduced prices.",
      "url": "https://finnhub.io/api/news?id=7d92d7b7741021982a383fc4de2cc1217781dc0f90208cc0b66ef8179cf823cb"
    }
  },
  {
    "ts": null,
    "headline": "Equities Advance Despite Looming Government Shutdown; Wall Street Posts Monthly Gains",
    "summary": "US equities advanced for a third straight session on Tuesday even as the world's biggest economy app",
    "url": "https://finnhub.io/api/news?id=252431a7a6608412e5fa155cdd8c5e04a190c6c57c959077f7c5b7e14deb1d5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759266460,
      "headline": "Equities Advance Despite Looming Government Shutdown; Wall Street Posts Monthly Gains",
      "id": 136943925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US equities advanced for a third straight session on Tuesday even as the world's biggest economy app",
      "url": "https://finnhub.io/api/news?id=252431a7a6608412e5fa155cdd8c5e04a190c6c57c959077f7c5b7e14deb1d5a"
    }
  },
  {
    "ts": null,
    "headline": "Drug Manufacturers Help Push US Equity Indexes Higher While Government Shutdown Looms",
    "summary": "US equity indexes rose at the close on Tuesday as gains in healthcare stocks helped offset declines",
    "url": "https://finnhub.io/api/news?id=99313131e7cf3d82c030e71c9dcfc47a822c2fd036838e289d7fe78aa2289d52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759266345,
      "headline": "Drug Manufacturers Help Push US Equity Indexes Higher While Government Shutdown Looms",
      "id": 136944051,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US equity indexes rose at the close on Tuesday as gains in healthcare stocks helped offset declines",
      "url": "https://finnhub.io/api/news?id=99313131e7cf3d82c030e71c9dcfc47a822c2fd036838e289d7fe78aa2289d52"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Soars on Trump’s New Drug Pricing Plan. Here’s Why.",
    "summary": "The president announced a federal government website that allows Pfizer to sell medicines at low prices to cash-paying consumers.",
    "url": "https://finnhub.io/api/news?id=04fbe0d5e9ce27db4ee3192e9532cb87df0019d8869b7be49ff119c8cd315884",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759265220,
      "headline": "Pfizer Stock Soars on Trump’s New Drug Pricing Plan. Here’s Why.",
      "id": 136944001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The president announced a federal government website that allows Pfizer to sell medicines at low prices to cash-paying consumers.",
      "url": "https://finnhub.io/api/news?id=04fbe0d5e9ce27db4ee3192e9532cb87df0019d8869b7be49ff119c8cd315884"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: Pfizer and Merck Jump; Payments Stocks Decline",
    "summary": "A pair of pharmaceutical giants spearheaded gains for other stocks in the industry on Tuesday, Sept. 30, 2025, while a new OpenAI partnership weighed on payments providers.",
    "url": "https://finnhub.io/api/news?id=531210fe660043dd7ec0376f0dee12cbdbcad9e3e169226211817f15d4b8deb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759263980,
      "headline": "S&P 500 Gains and Losses Today: Pfizer and Merck Jump; Payments Stocks Decline",
      "id": 136944146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A pair of pharmaceutical giants spearheaded gains for other stocks in the industry on Tuesday, Sept. 30, 2025, while a new OpenAI partnership weighed on payments providers.",
      "url": "https://finnhub.io/api/news?id=531210fe660043dd7ec0376f0dee12cbdbcad9e3e169226211817f15d4b8deb9"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Climb Late Afternoon",
    "summary": "Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index adding 2.5% and",
    "url": "https://finnhub.io/api/news?id=26948ee153551d9c68e40fca5a2f473c50dc0e50fb3bcaf5279c1d50f3af4b1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759261034,
      "headline": "Sector Update: Health Care Stocks Climb Late Afternoon",
      "id": 136944072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index adding 2.5% and",
      "url": "https://finnhub.io/api/news?id=26948ee153551d9c68e40fca5a2f473c50dc0e50fb3bcaf5279c1d50f3af4b1e"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Shares Skyrocket, What You Need To Know",
    "summary": "Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 5.7% in the afternoon session after the company announced positive results from its Phase 3 HYPERION trial for its drug, WINREVAIR™ (sotatercept-csrk).",
    "url": "https://finnhub.io/api/news?id=1e486297d61dc9b0c2c09823b6a8206b19ef5c7f23477f3d42aae12344320d56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759258283,
      "headline": "Merck (MRK) Shares Skyrocket, What You Need To Know",
      "id": 136944148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 5.7% in the afternoon session after the company announced positive results from its Phase 3 HYPERION trial for its drug, WINREVAIR™ (sotatercept-csrk).",
      "url": "https://finnhub.io/api/news?id=1e486297d61dc9b0c2c09823b6a8206b19ef5c7f23477f3d42aae12344320d56"
    }
  },
  {
    "ts": null,
    "headline": "Bernstein Maintains a Hold Rating on Merck & Co. (MRK)",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best large cap value stocks to buy now. Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Co., Inc. (NYSE:MRK) on September 25 without assigning a price target. Merck & Co., Inc. (NYSE:MRK) reported $15.8 billion in total worldwide sales in fiscal Q2 2025, […]",
    "url": "https://finnhub.io/api/news?id=946d369833eedfa121d5e1b7792e593b15a5d758c44ae03db1dc168416ce2846",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759258167,
      "headline": "Bernstein Maintains a Hold Rating on Merck & Co. (MRK)",
      "id": 136944149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best large cap value stocks to buy now. Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Co., Inc. (NYSE:MRK) on September 25 without assigning a price target. Merck & Co., Inc. (NYSE:MRK) reported $15.8 billion in total worldwide sales in fiscal Q2 2025, […]",
      "url": "https://finnhub.io/api/news?id=946d369833eedfa121d5e1b7792e593b15a5d758c44ae03db1dc168416ce2846"
    }
  },
  {
    "ts": null,
    "headline": "Equities Fall Intraday as Trump Says Government Shutdown 'Probably Likely'",
    "summary": "US benchmark equity indexes were lower intraday as President Donald Trump reportedly said that a fed",
    "url": "https://finnhub.io/api/news?id=ef28058bea8e31bed54cface43a02fb4ec7c4728294f49cdb83d1a79aaad5895",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759257020,
      "headline": "Equities Fall Intraday as Trump Says Government Shutdown 'Probably Likely'",
      "id": 136944150,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes were lower intraday as President Donald Trump reportedly said that a fed",
      "url": "https://finnhub.io/api/news?id=ef28058bea8e31bed54cface43a02fb4ec7c4728294f49cdb83d1a79aaad5895"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, Drug Stocks Leading S&P 500 on Pricing Deal with White House",
    "summary": "Pharmaceutical stocks were giving the market a big boost on Tuesday.  Merck was the top S&P 500 stock, while Pfizer was also among the leaders.  The second-best sector was consumer staples, up just 0.4%.",
    "url": "https://finnhub.io/api/news?id=f6b73f8912b1b3ecf39d793406b78752ef210cea9a2488de3fc00189f466fd4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759253468,
      "headline": "Pfizer, Drug Stocks Leading S&P 500 on Pricing Deal with White House",
      "id": 136944151,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks were giving the market a big boost on Tuesday.  Merck was the top S&P 500 stock, while Pfizer was also among the leaders.  The second-best sector was consumer staples, up just 0.4%.",
      "url": "https://finnhub.io/api/news?id=f6b73f8912b1b3ecf39d793406b78752ef210cea9a2488de3fc00189f466fd4e"
    }
  },
  {
    "ts": null,
    "headline": "US Equity Indexes Retreat as Federal Government Heads for Partial Shutdown",
    "summary": "US equity indexes declined after midday Tuesday as the dollar weakened and government bond yields re",
    "url": "https://finnhub.io/api/news?id=cae7a40ef466e488812b844773578fc53ff6c448225fc7fe2ea5e63066d4a97a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759252192,
      "headline": "US Equity Indexes Retreat as Federal Government Heads for Partial Shutdown",
      "id": 136937485,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US equity indexes declined after midday Tuesday as the dollar weakened and government bond yields re",
      "url": "https://finnhub.io/api/news?id=cae7a40ef466e488812b844773578fc53ff6c448225fc7fe2ea5e63066d4a97a"
    }
  },
  {
    "ts": null,
    "headline": "How Merck & Co. (MRK) Turns Robust Free Cash Flow Into Shareholder Value",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 10 Cash-Rich Dividend Stocks to Buy Right Now. Merck & Co., Inc. (NYSE:MRK) is an American multinational pharmaceutical company. Concerns are growing, however, as its top-selling cancer drug, Keytruda, starts losing patent protections in 2028. Since Keytruda is approximately half of Merck’s revenue, this is a […]",
    "url": "https://finnhub.io/api/news?id=7d853b4ce01b4178c2db8d155fa8d6adc2da5f4bdcb87b4f9f9a7c1af0713f0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759252065,
      "headline": "How Merck & Co. (MRK) Turns Robust Free Cash Flow Into Shareholder Value",
      "id": 136937681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 10 Cash-Rich Dividend Stocks to Buy Right Now. Merck & Co., Inc. (NYSE:MRK) is an American multinational pharmaceutical company. Concerns are growing, however, as its top-selling cancer drug, Keytruda, starts losing patent protections in 2028. Since Keytruda is approximately half of Merck’s revenue, this is a […]",
      "url": "https://finnhub.io/api/news?id=7d853b4ce01b4178c2db8d155fa8d6adc2da5f4bdcb87b4f9f9a7c1af0713f0e"
    }
  },
  {
    "ts": null,
    "headline": "Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio",
    "summary": "We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Verona Pharma plc is one of them. Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company developing therapies for respiratory diseases. Its lead product, Ohtuvayre (ensifentrine), is a first-in-class inhaled dual inhibitor of PDE3 and PDE4 for maintenance treatment of […]",
    "url": "https://finnhub.io/api/news?id=0b55bbd7372c137e9a44f669a93679d5f259a69b9b0f445e9f104d36f7b9aac5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759249979,
      "headline": "Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio",
      "id": 136937682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Verona Pharma plc is one of them. Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company developing therapies for respiratory diseases. Its lead product, Ohtuvayre (ensifentrine), is a first-in-class inhaled dual inhibitor of PDE3 and PDE4 for maintenance treatment of […]",
      "url": "https://finnhub.io/api/news?id=0b55bbd7372c137e9a44f669a93679d5f259a69b9b0f445e9f104d36f7b9aac5"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=aaba8396d793a94099dacaac0e4ef11f193324c0f3e94e98cddb76c77b9c2284",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759249800,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 136996529,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=aaba8396d793a94099dacaac0e4ef11f193324c0f3e94e98cddb76c77b9c2284"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Growth Catalysts Incoming",
    "summary": "Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous blockbuster drug. Read why REGN is a Buy.",
    "url": "https://finnhub.io/api/news?id=bb66c6e3504758db315ceacc9eb99a4641b7f297c884b7e7544ade750efc5d34",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759249535,
      "headline": "Regeneron: Growth Catalysts Incoming",
      "id": 136939389,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962383/image_1386962383.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous blockbuster drug. Read why REGN is a Buy.",
      "url": "https://finnhub.io/api/news?id=bb66c6e3504758db315ceacc9eb99a4641b7f297c884b7e7544ade750efc5d34"
    }
  },
  {
    "ts": null,
    "headline": "Initiative Tops Global New Business Rankings in Major Industry Comeback",
    "summary": "NEW YORK, September 30, 2025--Initiative has been ranked #1 globally in the COMvergence New Business Barometer H1 2025 rankings, marking a significant turnaround for the IPG Mediabrands agency. The agency also secured the top position in North America and leads new business rankings in six markets worldwide: the US, Belgium, Colombia, Denmark, Greece, and Portugal.",
    "url": "https://finnhub.io/api/news?id=488af1b1d432d161c76bb365da8e1d217f705c9a7b6cbd903782d15a6ef5e17c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759247940,
      "headline": "Initiative Tops Global New Business Rankings in Major Industry Comeback",
      "id": 136937684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "NEW YORK, September 30, 2025--Initiative has been ranked #1 globally in the COMvergence New Business Barometer H1 2025 rankings, marking a significant turnaround for the IPG Mediabrands agency. The agency also secured the top position in North America and leads new business rankings in six markets worldwide: the US, Belgium, Colombia, Denmark, Greece, and Portugal.",
      "url": "https://finnhub.io/api/news?id=488af1b1d432d161c76bb365da8e1d217f705c9a7b6cbd903782d15a6ef5e17c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Rises After WSJ Reports Company Will Cut Drug Costs",
    "summary": "Pfizer shares rose 2.8% Wednesday midday after The Wall Street Journal reported the pharmaceutical company would unveil a plan, alongside the Trump administration, to cut drug costs later Tuesday. Here's what to know:    The White House also plans to unveil a direct-to-consumer website for Americans to buy medication.",
    "url": "https://finnhub.io/api/news?id=6a633f4e3f072a0287e080921366b4652de528670a7645f164a019cf9fd539e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759247240,
      "headline": "Pfizer Stock Rises After WSJ Reports Company Will Cut Drug Costs",
      "id": 136937619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pfizer shares rose 2.8% Wednesday midday after The Wall Street Journal reported the pharmaceutical company would unveil a plan, alongside the Trump administration, to cut drug costs later Tuesday. Here's what to know:    The White House also plans to unveil a direct-to-consumer website for Americans to buy medication.",
      "url": "https://finnhub.io/api/news?id=6a633f4e3f072a0287e080921366b4652de528670a7645f164a019cf9fd539e4"
    }
  },
  {
    "ts": null,
    "headline": "Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?",
    "summary": "KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.",
    "url": "https://finnhub.io/api/news?id=5284b305c668b24cc9631e0ed846cb7a60ee4773224679e3226638e0f1dee45e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759241880,
      "headline": "Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?",
      "id": 136937686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.",
      "url": "https://finnhub.io/api/news?id=5284b305c668b24cc9631e0ed846cb7a60ee4773224679e3226638e0f1dee45e"
    }
  },
  {
    "ts": null,
    "headline": "7 Ideal \"Safer\" Dividend Buys From 61 September Graham Value All-Stars (GVAS)",
    "summary": "7 Ideal \"Safer\" Dividend Buys From 61 September Graham Value All-Stars (GVAS)",
    "url": "https://finnhub.io/api/news?id=7541357ddeb121bc1bfda61240900c5c56a2a915721b71f97a1ef21e576562a1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759234564,
      "headline": "7 Ideal \"Safer\" Dividend Buys From 61 September Graham Value All-Stars (GVAS)",
      "id": 136937269,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7541357ddeb121bc1bfda61240900c5c56a2a915721b71f97a1ef21e576562a1"
    }
  },
  {
    "ts": null,
    "headline": "Genmab Strikes $8 Billion Deal for Cancer Treatment Maker Merus",
    "summary": "BMO analysts said in a note Monday they were “encouraged” that Genmab’s acquisition “could start to spur broader M&A in the sector.”",
    "url": "https://finnhub.io/api/news?id=5e6093f3a5511a13b171e615c5fa9bdd4a507ce70ae291aa8eda81457ffd1f08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759228200,
      "headline": "Genmab Strikes $8 Billion Deal for Cancer Treatment Maker Merus",
      "id": 136937616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMO analysts said in a note Monday they were “encouraged” that Genmab’s acquisition “could start to spur broader M&A in the sector.”",
      "url": "https://finnhub.io/api/news?id=5e6093f3a5511a13b171e615c5fa9bdd4a507ce70ae291aa8eda81457ffd1f08"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Initiating \"Strong Buy\" On Shift To Qlex SC Injection For Solid Tumors",
    "summary": "Despite flat overall Q2 2025 sales, Keytruda's continued strong performance in oncology supports long-term bullish prospects for Merck. Read the latest analysis on the stock here.",
    "url": "https://finnhub.io/api/news?id=46e43cb6a034bfb103813c19f3a3d9ab16ed69477ea481937fccc03961c61e96",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759225994,
      "headline": "Merck: Initiating \"Strong Buy\" On Shift To Qlex SC Injection For Solid Tumors",
      "id": 136936476,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220590591/image_2220590591.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Despite flat overall Q2 2025 sales, Keytruda's continued strong performance in oncology supports long-term bullish prospects for Merck. Read the latest analysis on the stock here.",
      "url": "https://finnhub.io/api/news?id=46e43cb6a034bfb103813c19f3a3d9ab16ed69477ea481937fccc03961c61e96"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Partners with Variational AI to leverage AI in Enhancing Drug Development",
    "summary": "Merck & Co. Inc., (NYSE:MRK) is one of the best conservative stocks to buy now. On September 23, the company confirmed a strategic collaboration with Variational AI to leverage its Enki Platform in designing small-molecule drug candidates. Variational AI is to use a customized version of the Enki Platform, trained on Merck’s proprietary data, to […]",
    "url": "https://finnhub.io/api/news?id=3da67ba337e5fec0af6bd68159ec35cf6758113804b9a49a7d2a7a74a7eb028e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759219235,
      "headline": "Merck & Co., Inc. (MRK) Partners with Variational AI to leverage AI in Enhancing Drug Development",
      "id": 136934142,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co. Inc., (NYSE:MRK) is one of the best conservative stocks to buy now. On September 23, the company confirmed a strategic collaboration with Variational AI to leverage its Enki Platform in designing small-molecule drug candidates. Variational AI is to use a customized version of the Enki Platform, trained on Merck’s proprietary data, to […]",
      "url": "https://finnhub.io/api/news?id=3da67ba337e5fec0af6bd68159ec35cf6758113804b9a49a7d2a7a74a7eb028e"
    }
  },
  {
    "ts": null,
    "headline": "WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial",
    "summary": "RAHWAY, N.J., September 30, 2025--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. In the study, WINREVAIR reduced the risk of clinical worse",
    "url": "https://finnhub.io/api/news?id=a3bd5345312e49d6305f40587f5edc5d9ae1ede276751f565eb945cc0ffa58be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759217940,
      "headline": "WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial",
      "id": 136934143,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., September 30, 2025--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. In the study, WINREVAIR reduced the risk of clinical worse",
      "url": "https://finnhub.io/api/news?id=a3bd5345312e49d6305f40587f5edc5d9ae1ede276751f565eb945cc0ffa58be"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma’s retreat: Is NHS pricing behind investor pullbacks?",
    "summary": "Multinational pharmaceutical firms are pulling pack or pausing investments in the UK, blaming a lack of competitive drug pricing.View on euronews",
    "url": "https://finnhub.io/api/news?id=3364c0c8e93f31eda3774a6f0761852c9c6da22758f15db91170ab5c90068d65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759211535,
      "headline": "Big Pharma’s retreat: Is NHS pricing behind investor pullbacks?",
      "id": 136934023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Multinational pharmaceutical firms are pulling pack or pausing investments in the UK, blaming a lack of competitive drug pricing.View on euronews",
      "url": "https://finnhub.io/api/news?id=3364c0c8e93f31eda3774a6f0761852c9c6da22758f15db91170ab5c90068d65"
    }
  }
]